Fulgent Genetics Improves Loss Outlook As Revenue Reaches $90.4 Million

Spending discipline improves the annual outlook, but third-quarter margins remain below year-earlier levels.

Share
Fulgent Genetics Improves Loss Outlook As Revenue Reaches $90.4 Million

Fulgent Genetics, which runs laboratories and develops cancer treatments, improved its annual adjusted-loss and cash forecasts Thursday while reporting $90.4 million in third-quarter revenue, approximately 8% above a year earlier. The company attributed the better outlook to spending discipline in results accompanying its SEC filing, while keeping its annual sales forecast unchanged.

Better Forecasts, Thinner Margins

Fulgent now expects an annual adjusted loss of approximately $46.0–$50.0 million, or approximately $1.65–$1.75 per share. Its 2026 revenue forecast remains $330.0–$340.0 million.

FLGT shares soared about 16% to $21.65 in Friday trading.

The quarter's profitability was weaker than a year earlier. Gross profit—the money left after delivering services—was $31.9 million, with a margin of 35.3%, compared with 42.2% a year earlier. The margin nevertheless improved from 30.1% in the second quarter.

Fulgent lost $13.2 million, or $0.48 per share, under standard accounting. Its adjusted result was a loss of $2.4 million, or $0.09 per share, compared with adjusted earnings of $4.521 million a year earlier. Adjustments included removing stock-based pay and amortization of intangible assets.

Paul Kim, Fulgent's chief financial officer, credited improved collection rates for the quarter's results. “We made great progress to address the billing system issue,” Kim said Thursday.

Pathology Grows, Precision Diagnostics Shrinks

Growth was uneven across the laboratory business. For the first nine months, anatomic pathology generated $103.5 million, up 30% from a year earlier. Precision diagnostics revenue fell 13% to $123.5 million, while services for pharmaceutical and biotechnology companies grew 13% to $19.9 million.

Fulgent's laboratory offerings span pathology, rare-disease testing, hereditary cancer and reproductive health. Picture, its telemedicine platform, lets consumers initiate testing. The therapeutic business is developing the cancer drug candidates FID-007 and FID-022 using a nanoencapsulation platform; both are in clinical trials.

The laboratory expansion includes Bako and StrataDx, bought on March 17, 2026, for an adjusted purchase price of $56.4 million. Those purchases added dermatopathology expertise and laboratories in Georgia and Massachusetts.

Ming Hsieh, Fulgent's chairman and chief executive officer, said the company continues integrating artificial intelligence into laboratory workflows. “We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality,” Hsieh said in the release.

Cash Forecast Assumes A Buyback Pause

Fulgent ended the third quarter with $652.4 million across cash, cash equivalents, restricted cash and marketable-securities investments. Management expects approximately $630.0 million at year-end.

That forecast incorporates $64.1 million spent on share repurchases through September 30, 2026. The annual per-share loss forecast also accounts for a reduction of 4.1 million shares from the repurchase program over that period.

The year-end cash estimate assumes $13 million in capital purchases, $21 million spent on therapeutic development and no further near-term share repurchases.

Fulgent's improved outlook rests on spending restraint: the company still expects an annual adjusted loss, with its revenue forecast unchanged.

Sources

More on Fulgent Genetics

All Fulgent Genetics (FLGT) coverage →